Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Breast Cancer Res Treat. 2016 Feb 9;155(3):431–440. doi: 10.1007/s10549-016-3698-y

Fig. 3.

Fig. 3

Effect of targeting HER3 or β1 integrin on tumor signaling in vivo. Two representative mice from each treatment arm of Fig. 2 were sacrificed and tumor lysates were assayed by Western blotting as indicated. The relative intensities of the HER3 and β1 integrin bands are quantitatively shown below as an average of the two samples in each arm